Covid-19 Impact on Medical Cannabis Market, Global Research Reports 2020-2021

2 Global Medical Cannabis Quarterly Market Size Analysis

• 2.1 Medical Cannabis Business Impact Assessment - COVID-19
  • 2.1.1 Global Medical Cannabis Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Medical Cannabis Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Medical Cannabis Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Medical Cannabis Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Medical Cannabis Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Medical Cannabis Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Medical Cannabis Market
• 3.5 Key Manufacturers Medical Cannabis Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Medical Cannabis Segments, By Type

• 4.1 Introduction
  • 1.4.1 Tetrahydrocannabinol (THC)
  • 1.4.2 Cannabidiol (CBD)
• 4.2 By Type, Global Medical Cannabis Market Size, 2019-2021
  • 4.2.1 By Type, Global Medical Cannabis Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Medical Cannabis Price, 2020-2021

5 Impact of Covid-19 on Medical Cannabis Segments, By Application

• 5.1 Overview
  • 5.5.1 Pain
  • 5.5.2 Arthritis
  • 5.5.3 Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications)
  • 5.5.4 Others
• 5.2 By Application, Global Medical Cannabis Market Size, 2019-2021
  • 5.2.1 By Application, Global Medical Cannabis Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Medical Cannabis Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 BOL Pharma
  • 7.1.1 BOL Pharma Business Overview
  • 7.1.2 BOL Pharma Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.1.3 BOL Pharma Medical Cannabis Product Introduction
  • 7.1.4 BOL Pharma Response to COVID-19 and Related Developments
• 7.2 Tilray
  • 7.2.1 Tilray Business Overview
  • 7.2.2 Tilray Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.2.3 Tilray Medical Cannabis Product Introduction
  • 7.2.4 Tilray Response to COVID-19 and Related Developments
• 7.3 Medreleaf Corporation
  • 7.3.1 Medreleaf Corporation Business Overview
  • 7.3.2 Medreleaf Corporation Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.3.3 Medreleaf Corporation Medical Cannabis Product Introduction
  • 7.3.4 Medreleaf Corporation Response to COVID-19 and Related Developments
• 7.4 Aurora Cannabis, Inc
  • 7.4.1 Aurora Cannabis, Inc Business Overview
  • 7.4.2 Aurora Cannabis, Inc Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.4.3 Aurora Cannabis, Inc Medical Cannabis Product Introduction
  • 7.4.4 Aurora Cannabis, Inc Response to COVID-19 and Related Developments
• 7.5 Canopy Growth Corporation
  • 7.5.1 Canopy Growth Corporation Business Overview
  • 7.5.2 Canopy Growth Corporation Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.5.3 Canopy Growth Corporation Medical Cannabis Product Introduction
  • 7.5.4 Canopy Growth Corporation Response to COVID-19 and Related Developments
• 7.6 Insys Therapeutics, Inc
  • 7.6.1 Insys Therapeutics, Inc Business Overview
  • 7.6.2 Insys Therapeutics, Inc Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.6.3 Insys Therapeutics, Inc Medical Cannabis Product Introduction
  • 7.6.4 Insys Therapeutics, Inc Response to COVID-19 and Related Developments
• 7.7 Aphria, Inc
  • 7.7.1 Aphria, Inc Business Overview
  • 7.7.2 Aphria, Inc Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.7.3 Aphria, Inc Medical Cannabis Product Introduction
  • 7.7.4 Aphria, Inc Response to COVID-19 and Related Developments
• 7.8 MGC Pharmaceuticals Limited
  • 7.8.1 MGC Pharmaceuticals Limited Business Overview
  • 7.8.2 MGC Pharmaceuticals Limited Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.8.3 MGC Pharmaceuticals Limited Medical Cannabis Product Introduction
  • 7.8.4 MGC Pharmaceuticals Limited Response to COVID-19 and Related Developments
• 7.9 GW Pharmaceuticals, plc
  • 7.9.1 GW Pharmaceuticals, plc Business Overview
  • 7.9.2 GW Pharmaceuticals, plc Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.9.3 GW Pharmaceuticals, plc Medical Cannabis Product Introduction
  • 7.9.4 GW Pharmaceuticals, plc Response to COVID-19 and Related Developments
• 7.10 Medical Marijuana Inc
  • 7.10.1 Medical Marijuana Inc Business Overview
  • 7.10.2 Medical Marijuana Inc Medical Cannabis Quarterly Production and Revenue, 2020
  • 7.10.3 Medical Marijuana Inc Medical Cannabis Product Introduction
  • 7.10.4 Medical Marijuana Inc Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Medical Cannabis Supply Chain Analysis
  • 8.1.1 Medical Cannabis Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Medical Cannabis Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Medical Cannabis Distribution Channels
  • 8.2.2 Covid-19 Impact on Medical Cannabis Distribution Channels
  • 8.2.3 Medical Cannabis Distributors
• 8.3 Medical Cannabis Customers

9 Key Findings

10 Appendix

• 10.1 About Us